Baron Capital14 min
Attractive SMID Cap Stocks Amid Tech Turbulence
Interview
Market Rotation Drivers
- Small and mid-cap (SMID) stocks are currently under-allocated, representing only 3% of the Russell 3000 versus a historical norm of 7.5%.
- Valuation metrics suggest upside potential, with the Russell 2500 Growth index trading at 21.5x forward earnings, roughly half a multiple below the S&P 500 and within its typical 20–22x range.
- Growth differentiation is evident in sales projections: the Barron SMID ETF (BCSM) is projected to grow at 20%, compared to 16% for the S&P 500 and 11% for next year's sales.
- The macroeconomic environment supports this shift through inflation trending below 3% and potential GDP growth forecasts reaching 5%.
Sector-Specific Shifts and AI Dynamics
- Capital expenditure for AI data centers is surging from $200 billion in 2024 to an expected $400 billion in 2025 and $650 billion subsequently.
- Hardware and semiconductor providers (e.g., Coherent) are benefiting directly from this build-out, while software companies face valuation compression.
- Software valuations have tightened significantly, with small-cap software down 40% year-to-date and some lower-growth entities trading at 3.5x forward sales, below 2015 levels.
- Specific software stocks like Datadog and Dynatrace are identified as resilient despite sector-wide pressure due to their embedded network infrastructure roles.
- Dynatrace trades at 13x free cash flow while growing FCF in the high teens.
- Risk exists for seat-based business models in code generation and legal software where AI can displace human labor tasks.
Key Holdings and Thematic Investments
- Axon: Selected for its hybrid "atoms and electrons" model, leveraging physical sensors (body cams, tasers) to feed proprietary AI data that cannot be replicated by software-only agentic models.
- Tempus AI: Positioned at the intersection of healthcare and AI, utilizing a proprietary database of genetic and outcomes-based data to aid drug development and cancer diagnostics.
- Biologics Supply Chain: Investments include Repligen (biologic manufacturing equipment) and Stevanato (glass tubing for auto-injectors used in GLP-1 and PCSK-9 therapies).
Investment Strategy and Forward Outlook
- Barron Capital employs a three-to-five-year horizon focused on identifying companies capable of doubling or tripling free cash flow.
- The firm emphasizes deep fundamental research, including management interviews and competitor analysis, to navigate the volatility of small-cap markets.
- A broader market is viewed as economically healthier, reducing reliance on mega-cap concentration and potentially benefiting consumer sectors via tax rebates.
- The strategy expects the current valuation disconnect between small/mid-caps and large-caps to normalize as the rate cycle transitions toward lower rates.